CureDM receives patent allowance for novel islet neogenesis program

CureDM, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering a Human proIslet Peptide (HIP) and methods related to its use and administration for treating type 1 diabetes. This newly allowed patent application broadly protecting a particular HIP peptide and certain uses within CureDM’s HIP peptide program is the second U.S. application to be issued for CureDM’s novel islet neogenesis program. The original composition of matter patent for CureDM’s lead development candidate, Pancreate™ (HIP), was issued in 2008.

CEO, H. Joseph Reiser, PhD explains, “We are extremely pleased with this timely expansion of our patent portfolio which further validates our novel human peptide based platform to treat diabetes. Importantly, this patent also expands our treatment approach to type 1 diabetes by allowing different treatment regimes including combination therapy.”

The claims of the newly allowed patent application cover a particular HIP peptide sequence and the pharmaceutical composition containing the HIP peptide. Additional coverage also pertains to methods of using the HIP peptide to treat type 1 diabetes alone or in combination with agents that stimulate pancreatic islet cell regeneration, or agents that inhibit, block or destroy autoimmune cells that target pancreatic cells.

This newly allowed patent application is solely owned by CureDM.